Antibody responses after hepatitis B vaccination among maintenance haemodialysis patients

Bangladesh Med Res Counc Bull. 2011 Dec;37(3):88-91. doi: 10.3329/bmrcb.v37i3.9119.

Abstract

In haemodialysis patients, hepatitis B virus infection has higher mortality and is more likely to result in the carrier state. Although Hepatitis B vaccine is effective in producing protection against HBV infection, the antibody response may be variable. In this study, seroprotection rate of hepatitis B vaccine in maintenance haemodialysis patients was studied after primary vaccination and after completion of the full vaccine regime. 50 unvaccinated patients on maintenance haemodialysis were included in this study. Patients negative for HBsAg, Anti-HBc (total) and Anti-HCV were vaccinated with 40 microg of Engerix B following a schedule of 0, 1, and 2 months. The antibody titer was tested at 3rd month and if the titer was < 10 or between 10-100 mIU/ml, they were given another 4th dose of vaccine at 6th month, and their antibody titer was tested again at 7th month. In maintenance haemodialysis patients, the response rate to HBV vaccine was 44% after the primary vaccination and 80% after completion of the full vaccine regime.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antibody Formation / drug effects*
  • Antibody Formation / immunology
  • Female
  • Hepatitis B Antibodies / blood
  • Hepatitis B Antibodies / drug effects*
  • Hepatitis B Antibodies / immunology
  • Hepatitis B Surface Antigens / blood
  • Hepatitis B Surface Antigens / drug effects*
  • Hepatitis B Surface Antigens / immunology
  • Hepatitis B Vaccines / administration & dosage
  • Hepatitis B Vaccines / pharmacology*
  • Hepatitis B virus / immunology*
  • Humans
  • Kidney Diseases / therapy
  • Male
  • Middle Aged
  • Renal Dialysis*
  • Young Adult

Substances

  • Hepatitis B Antibodies
  • Hepatitis B Surface Antigens
  • Hepatitis B Vaccines